呼市内痔危害呼和浩特治疗脱肛大概多少费用,呼市痔疮疼痛的治疗,托克托县肛肠医院好么,呼和浩特市男性大便出血怎么办,清水河县较有知名度的肛肠医院,新城区肛肠医院医师,痔疮呼市东大

BEIJING, Sept. 6 (Xinhuanet) -- San Francisco police said they had helped Apple search for a "lost item," following reports saying that a prototype of Apple's yet-to-be-released iPhone 5 had gone missing in July.Last week, technology news website CNET reported that an Apple employee lost at a tequila bar in San Francisco in July a prototype of iPhone 5, a new version of the company's mobile phone expected to be released in September or October.The San Francisco Police Department said in a press release that after the missing device was tracked using GPS technology to a San Francisco house, four police officers and two Apple employees visited the home."Apple employees called Mission police station directly, wanting assistance in tracking down a lost item," the statement said."The two Apple employees met with the resident and then went into the house to look for the lost item," it said. "The Apple employees did not find the lost item and left the house."Police did not say exactly what Apple had lost, but media reports found the file of San Francisco police's Friday press release about the hunt was named "iphone5.doc" -- an apparent hint of the new mobile device.A 22-year-old resident of the home, identified by SF Weekly as Sergio Calderon, told the newspaper that he has visited the bar where the phone was reportedly lost but he did not have the device.Calderon said the search of his house took place in July when police had traced the phone to the house using satellite positioning software on the device, but did not find anything in the house.Apple has declined to comment on the matter.Last year, an employee of the company lost a prototype iPhone 4 in a Redwood City bar before it was released. The details of the phone ware then unveiled by technology blog Gizmodo.Criminal charges have been filed against the man who found the prototype and another who brokered the deal to sell it to Gizmodo. Both men pleaded not guilty on Thursday.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

WASHINGTON, June 14 (Xinhua) -- Eating a low-carbohydrate, high- protein diet may reduce the risk of cancer and slow the growth of tumors already present, according to a study published Tuesday in Cancer Research, a journal of the American Association for Cancer Research.The study was conducted in mice, but the scientists involved agree that the strong biological findings are definitive enough that an effect in humans can be considered."This shows that something as simple as a change in diet can have an impact on cancer risk," said lead researcher Gerald Krystal, a scientist at the British Columbia Cancer Research Center.Krystal and his colleagues implanted various strains of mice with human tumor cells or with mouse tumor cells and assigned them to one of two diets. The first diet, a typical Western diet, contained about 55 percent carbohydrate, 23 percent protein and 22 percent fat. The second, which is somewhat like a South Beach diet but higher in protein, contained 15 percent carbohydrate, 58 percent protein and 26 percent fat. They found that the tumor cells grew consistently slower on the second diet.As well, mice genetically predisposed to breast cancer were put on these two diets and almost half of them on the Western diet developed breast cancer within their first year of life while none on the low-carbohydrate, high-protein diet did. Interestingly, only one on the Western diet reached a normal life span ( approximately 2 years), with 70 percent of them dying from cancer while only 30 percent of those on the low-carbohydrate diet developed cancer and more than half these mice reached or exceeded their normal life span.Krystal and colleagues also tested the effect of an mTOR inhibitor, which inhibits cell growth, and a COX-2 inhibitor, which reduces inflammation, on tumor development, and found these agents had an additive effect in the mice fed the low-carbohydrate, high-protein diet.When asked to speculate on the biological mechanism, Krystal said that tumor cells, unlike normal cells, need significantly more glucose to grow and thrive. Restricting carbohydrate intake can significantly limit blood glucose and insulin, a hormone that has been shown in many independent studies to promote tumor growth in both humans and mice.Furthermore, a low-carbohydrate, high-protein diet has the potential to both boost the ability of the immune system to kill cancer cells and prevent obesity, which leads to chronic inflammation and cancer.

BEIJING, Aug. 22 (Xinhuanet) -- U.S. presidential candidate Rick Perry's controversial stem-cell treatment may inspire desperate patients to follow his lead while causing medical and legal concerns, according to media reports Monday.The Texas governor underwent a procedure on July 1 where stem cells, made from fat taken from his body, were put into his bloodstream to see if they might find their way to fix a bad back.The treatment carries potential risks ranging from blood clots to infection to cancer and may even run afoul of federal rules, doctors say. File photo of U.S. Republican presidential candidate Texas Governor Rick Perry."As a highly influential person of power, Perry’s actions have the unfortunate potential to push desperate patients into the clinic of quacks,” Harvard’s stem cell expert George Daley told the Associated Press.Worries about the safety and wisdom of this treatment are widespread among stem cell researchers as such a treatment has not been thoroughly vetted by researchers or approved by the FDA.

BEIJING, Aug. 13 (Xinhua) -- The quality of the products China exported to the European Union (EU) improved during the first half of this year due to strict quality control measures, according to quality control authorities.The number of quality complaints made by the EU regarding Chinese imports declined by 45 percent in the first half of 2011, according to the General Administration of Quality Supervision, Inspection and Quarantine (AQSIQ).The administration attributed the improved quality to its nationwide crackdown on counterfeited and substandard products.The administration launched a nationwide quality checkup in the first half of this year. Of the 4,815 batches of products that the quality control authorities checked between January and June, just 9.4 percent failed quality tests, 1.7 percentage points lower than that of the same period of last year, according to the administration.A total of 218,000 counterfeiting cases have been investigated so far this year, involving goods worth a total of 9.5 billion yuan (1.49 billion U.S. dollars), the administration said.